MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-31-2026
VolitionRx Limited Book Value 2011-2026 | VNRX
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value VolitionRx Limited
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -35.6 M | -26.1 M | -8.71 M | -3.13 M | 17.7 M | - | 14.2 M | 12.1 M | 9.96 M | 21.2 M | 6.04 M | 368 K | 680 K | 840 K | -130 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 21.2 M | -35.6 M | 675 K |
Quarterly Book Value VolitionRx Limited
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -35.9 M | -33.1 M | -29 M | -26.1 M | -22.6 M | -22.9 M | -16.6 M | -8.71 M | -2.85 M | 5.12 M | -2.98 M | -3.13 M | 2.84 M | 4.08 M | 10.8 M | 17.7 M | 21.2 M | 26.6 M | 31.2 M | 16.3 M | 16.3 M | 16.3 M | 16.3 M | 14.2 M | 14.2 M | 14.2 M | 14.2 M | 12.1 M | 12.1 M | 12.1 M | 12.1 M | 9.96 M | 9.96 M | 9.96 M | 9.96 M | 21.2 M | 21.2 M | 21.2 M | 21.2 M | 6.04 M | 6.04 M | 6.04 M | 6.04 M | 368 K | 368 K | 368 K | 368 K | 681 K | 681 K | 681 K | 681 K | 834 K | 834 K | 834 K | 834 K | 1.09 M | 1.09 M | 1.09 M | 1.09 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 31.2 M | -35.9 M | 4.18 M |
Book Value of other stocks in the Diagnostics research industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
77.2 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
5.39 B | $ 115.55 | 1.0 % | $ 35.1 B |  USA |
|
Akumin
AKU
|
141 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Accelerate Diagnostics
AXDX
|
-22.3 M | - | -61.36 % | $ 2.46 M | USA |
 |
Aspira Women's Health
AWH
|
-6.93 M | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
8.86 M | - | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
17.8 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
-1.45 M | - | - | $ 9.42 M |  Israel |
 |
Co-Diagnostics
CODX
|
20.6 M | $ 1.67 | -2.34 % | $ 2.22 M | USA |
 |
CareDx, Inc
CDNA
|
303 M | $ 21.23 | 5.83 % | $ 1.13 B | USA |
 |
Castle Biosciences
CSTL
|
456 M | $ 24.46 | 3.25 % | $ 679 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
16.7 M | - | - | $ 562 M |  Britain |
 |
DermTech
DMTK
|
57.2 M | - | -11.32 % | $ 2.94 M | USA |
 |
Enzo Biochem
ENZ
|
56.1 M | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
2.4 B | - | - | $ 19.8 B | USA |
 |
Fulgent Genetics
FLGT
|
1.13 B | $ 16.31 | 1.75 % | $ 493 M | USA |
 |
Global Cord Blood Corporation
CO
|
4.88 B | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
132 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
16.4 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
548 M | - | 0.12 % | $ 80.1 M | China |
 |
Charles River Laboratories International
CRL
|
3.21 B | $ 169.8 | 1.23 % | $ 8.42 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
1.32 B | - | - | $ 10.7 B | USA |
 |
Illumina
ILMN
|
6.3 B | $ 127.88 | 1.95 % | $ 20.3 B | USA |
 |
Guardant Health
GH
|
-99.3 M | $ 88.91 | 1.18 % | $ 11.1 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
5.39 M | - | -20.0 % | $ 1.06 M | USA |
 |
Heska Corporation
HSKA
|
422 M | - | - | $ 1.31 B | USA |
 |
Lantheus Holdings
LNTH
|
1.09 B | $ 84.33 | 1.82 % | $ 5.69 B | USA |
 |
Interpace Biosciences
IDXG
|
22.4 M | $ 1.98 | -2.37 % | $ 8.76 M | USA |
 |
Medpace Holdings
MEDP
|
459 M | $ 410.54 | 4.35 % | $ 11.8 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
11 B | $ 27.47 | -0.58 % | $ 20 B |  Niderland |
 |
Motus GI Holdings
MOTS
|
2.69 M | - | -34.28 % | $ 263 K | Israel |
 |
QIAGEN N.V.
QGEN
|
6.15 B | - | - | $ 10.6 B | Niderland |
 |
Neogen Corporation
NEOG
|
2.07 B | $ 9.54 | 2.03 % | $ 2.07 B | USA |
 |
Biomerica
BMRA
|
4.1 M | $ 2.14 | -0.47 % | $ 4.92 M | USA |
 |
National Research Corporation
NRC
|
14 M | $ 17.23 | -0.12 % | $ 386 M | USA |
 |
ICON Public Limited Company
ICLR
|
9.52 B | $ 102.17 | -3.92 % | $ 8.43 B |  Irlanda |
 |
Laboratory Corporation of America Holdings
LH
|
8.64 B | $ 263.8 | -0.43 % | $ 21.9 B | USA |
 |
Celcuity
CELC
|
101 M | $ 121.03 | 6.58 % | $ 5.66 B | USA |
 |
OpGen
OPGN
|
7.38 M | - | -16.95 % | $ 1.54 M | USA |
 |
NeoGenomics
NEO
|
837 M | $ 8.29 | 4.8 % | $ 1.06 B | USA |
 |
Myriad Genetics
MYGN
|
368 M | $ 4.78 | -0.21 % | $ 443 M | USA |
 |
Natera
NTRA
|
706 M | $ 203.75 | 1.3 % | $ 20.1 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
16.2 B | $ 196.27 | -1.66 % | $ 21.8 B | USA |
 |
Invitae Corporation
NVTA
|
102 M | - | - | $ 21.2 M | USA |
 |
PerkinElmer
PKI
|
7.25 B | - | -0.91 % | $ 14.7 B | USA |
 |
Organovo Holdings
ONVO
|
10.5 M | - | -2.3 % | $ 19.4 M | USA |
 |
Precipio
PRPO
|
14.6 M | $ 28.0 | 3.57 % | $ 44.9 M | USA |
 |
Personalis
PSNL
|
203 M | $ 6.1 | 3.39 % | $ 361 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
1.85 B | $ 20.69 | 0.49 % | $ 223 M | China |
 |
Pacific Biosciences of California
PACB
|
5.35 M | $ 1.56 | -0.64 % | $ 468 M | USA |